Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Participants With Presumed Nonalcoholic Steatohepatitis (NASH)
Public ClinicalTrials.gov record NCT03823703. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Patients With Presumed Nonalcoholic Steatohepatitis (NASH)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This phase 2, double blind, placebo-controlled, randomized study is to assess the safety and efficacy of miricorilant (CORT118335) in patients with presumed Nonalcoholic Steatohepatitis (NASH).
Study identification
- NCT ID
- NCT03823703
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 12 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 75 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 4, 2020 (Actual)
- Primary completion
- Apr 5, 2021 (Actual)
- Completion
- Apr 5, 2021 (Actual)
- Last update posted
- Aug 31, 2022
2020 – 2021
United States locations
- U.S. sites
- 15
- U.S. states
- 7
- U.S. cities
- 14
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Site 207 | Chandler | Arizona | 85224 | — |
| Site 208 | Glendale | Arizona | 85306 | — |
| Site 209 | Tucson | Arizona | 85712 | — |
| Site 227 | Los Angeles | California | 90057 | — |
| Site 214 | Panorama City | California | 91402 | — |
| Site 233 | Santa Ana | California | 92704 | — |
| Site 234 | Port Orange | Florida | 32127 | — |
| Site 210 | Sarasota | Florida | 34240 | — |
| Site 228 | Kansas City | Missouri | 61434 | — |
| Site 232 | East Syracuse | New York | 13057 | — |
| Site 211 | Austin | Texas | 78757 | — |
| Site 213 | Edinburg | Texas | 78539 | — |
| Site 215 | Edinburg | Texas | 78539 | — |
| Site 212 | San Antonio | Texas | 78229 | — |
| Site 226 | Seattle | Washington | 98105 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03823703, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 31, 2022 · Synced Oct 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT03823703 live on ClinicalTrials.gov.